

Supplementary file 2 Proportion of patients achieving a sustained viral response (SVR) among those initiated on (and with a known response to) HCV treatment in Scotland, by patient characteristics and financial year

		Financial year (April to March) of HCV treatment initiation							
		Pre-DAA era				DAA era			
		2010/11	2011/12	2012/13	2013/14	2014/15	2015/16	2016/17	2017/18 (Apr-Sep) ²
Total initiated (and on clinical database) (N1)		967	938	1014	943	1192	1642	1632	909
Proportion with a known response to treatment, % (N2/N1)		80 (779/967)	77 (726/938)	80 (815/1014)	72 (680/943)	82 (980/1192)	89 (1455/1642)	84 (1375/1632)	74 (670/909)
% SVR (n/N2)*		73 (571/779)	75 (546/726)	78 (636/815)	79 (535/680)	88 (867/980)	96 (1391/1455)	96 (1324/1375)	97 (648/670)
By Genotype	1	64 (208/325)	66 (182/277)	75 (292/388)	76 (242/319)	86 (378/442)	97 (838/863)	97 (747/771)	96 (302/314)
	3	79 (326/412)	81 (325/400)	81 (293/363)	79 (251/317)	91 (413/454)	93 (451/484)	96 (461/480)	98 (311/317)
	other / NK	88 (37/42)	80 (39/49)	80 (51/64)	95 (42/44)	90 (76/84)	94 (102/108)	94 (116/124)	90 (35/39)
		75	78	82	82	90	96	97	97
Compensated cirrhosis at treatment initiation	No	57 (526/700)	53 (497/634)	61 (553/678)	62 (461/561)	85 (568/628)	95 (953/992)	95 (991/1025)	95 (502/516)
	Yes	73 (45/79)	75 (49/92)	78 (83/137)	78 (74/119)	88 (299/352)	89 (438/463)	88 (333/350)	85 (146/154)
By Treatment Regimen¹	IFN-Based	73 (571/779)	75 (537/713)	78 (623/801)	78 (502/645)	88 (274/310)	89 (145/163)	88 (80/91)	85 (11/13)
	IFN-Sparing	NA	80 (4/5)	100 (NA)	100 (15/15)	88 (353/401)	97 (217/224)	96 (127/132)	100 (11/11)
	IFN-Free	NA	63 (5/8)	93 (13/14)	90 (18/20)	89 (240/269)	96 (1029/1068)	97 (1117/1152)	97 (626/646)
		NA	63 (5/8)	93 (13/14)	90 (18/20)	89 (240/269)	96 (1029/1068)	97 (1117/1152)	97 (626/646)

¹ IFN-Based includes pegylated interferon + ribavirin ± telaprevir/boceprevir ; IFN-Sparing includes pegylated interferon + ribavirin + sofosbuvir; pegylated interferon + ribavirin + simeprevir ; IFN-Free includes any treatment regimen not containing interferon. ² Data relating to those initiated in the first six months of 2017/18 financial year presented, to allow a minimum of six-months follow-up time to capture SVR status on the clinical database. HCV, hepatitis C virus; NK, not known; NA, not applicable; IFN, interferon.

Supplementary file 3 Results of sensitivity analysis for the segmented regression analysis, considering two broader definitions for the outcome measure of new presentations with HCV-related DC

Outcome measure		a) New presentations with HCV-related DC, N (%)		b) Segmented Poisson regression analysis					
		Pre-DAA Era (Jan 2000 to Dec 2014)	DAA Era (Jan 2015 to Dec 2018)	Pre-DAA Era Slope per 6-month period		Change in Slope per 6-month period		DAA Era Slope per 6-month period	
				RR (95% CI)	p-value	RR (95% CI)	p-value	RR (95% CI)	p-value
i)	First-time hospital admission with (or otherwise death from) DC, among those with chronic HCV diagnosis	1415	451	1.04 (1.04–1.05)	<0.001	0.89 (0.86 – 0.91)	<0.001	0.92 (0.90–0.95)	<0.001
ii)	First-time hospital admission with DC, among those with chronic HCV diagnosis (including those with not known chronic status at diagnosis)	1366	412	1.04 (1.03–1.05)	<0.001	0.88 (0.86 – 0.91)	<0.001	0.92 (0.90–0.94)	<0.001

Supplementary file 4 Characteristics of chronic HCV infected patients with compensated cirrhosis in Scotland according to whether diagnosed with cirrhosis during the pre-DAA era (January 2011 to May 2014) or in the DAA era (June 2014 to March 2018)

		Pre-DAA era	DAA era
		N (%)	N (%)
Total		1015 (100)	1234 (100)
Sex	Female	275 (27)	309 (25)
	Male	740 (73)	925 (75)
Age at cirrhosis diagnosis (years)	<50	661 (65)	741 (60)
	50+	354 (35)	493 (40)
Risk group for HCV acquisition	PWID	639 (63)	809 (66)
	Non-PWID/not known	376 (37)	425 (34)
Alcohol consumption history	>50 units/wk	350 (34)	393 (32)
	≤50 units/wk (and not known)	665 (66)	841 (68)
Genotype	G1	398 (39)	532 (43)
	G3	491 (48)	550 (45)
	Other/NK	126 (12)	152 (12)
Child-Pugh class	A	706 (70)	850 (69)
	B	26 (3)	36 (3)
	Not known	283 (27)	348 (28)
Prior antiviral treatment	Naïve	766 (75)	1110 (90)
	Experienced	249 (25)	124 (10)